Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Over 50 leading institutions and centers for psychedelic research worldwide
Institutions
50
Total Studies
403
Countries
15
40
Studies
About
The world's first academic center dedicated to psychedelic research, producing groundbreaking brain imaging studies on LSD and psilocybin. Leads major clinical trials for treatment-resistant depression.
Director / Lead
David Nutt
Focus Areas
30
Studies
About
Founded in 1986, MAPS is the leading organization advancing MDMA-assisted therapy for PTSD through phase 3 clinical trials. A pioneer in psychedelic research advocacy and education.
Director / Lead
Rick Doblin
Website
maps.orgFocus Areas
25
Studies
About
One of the world's leading psychedelic research centers, pioneering psilocybin studies for depression, addiction, and end-of-life distress. Home to landmark FDA breakthrough therapy trials.
Director / Lead
Matthew Johnson
Website
hopkinspsychedelic.orgFocus Areas
22
Studies
About
A world-leading psychopharmacology group studying the acute and therapeutic effects of LSD, psilocybin, and MDMA. Produced foundational controlled studies on LSD pharmacology.
Director / Lead
Matthias Liechti
Website
www.unibas.chFocus Areas
20
Studies
About
Pioneered modern psychedelic neuroscience with foundational PET and fMRI studies on psilocybin. Led by Franz Vollenweider, whose work defined the serotonergic model of psychedelic action.
Director / Lead
Franz Vollenweider
Website
www.uzh.chFocus Areas
15
Studies
About
A pioneering policy and research foundation advancing the scientific understanding of psychedelics and cannabis. Funded seminal brain imaging studies with Imperial College London.
Director / Lead
Amanda Feilding
Website
beckleyfoundation.orgFocus Areas
15
Studies
About
A pioneering Brazilian institution with extensive research on ayahuasca and its therapeutic potential. Conducted landmark studies on ayahuasca for treatment-resistant depression.
Director / Lead
Jaime Hallak
Website
www5.usp.brFocus Areas
12
Studies
About
A major academic center studying psilocybin-assisted therapy for alcohol use disorder and MDMA-assisted therapy for PTSD. Published pivotal trials on existential distress in cancer patients.
Director / Lead
Michael Bogenschutz
Focus Areas
12
Studies
About
A mental health care biotech company pioneering the development of COMP360 psilocybin therapy for treatment-resistant depression. Operates the largest psilocybin clinical trial program globally.
Director / Lead
George Goldsmith
Website
compasspathways.comFocus Areas
12
Studies
About
A leading Dutch psychopharmacology department studying the cognitive and emotional effects of psychedelics. Conducts naturalistic and controlled studies on psilocybin and ayahuasca.
Director / Lead
Kim Kuypers
Website
www.maastrichtuniversity.nlFocus Areas
10
Studies
About
One of the earliest academic programs studying psilocybin for end-of-life anxiety in cancer patients. Continues research into psychedelic-assisted therapies for mood and anxiety disorders.
Director / Lead
Charles Grob
Website
www.ucla.eduFocus Areas
10
Studies
About
Conducting clinical trials of psilocybin for treatment-resistant depression in collaboration with Compass Pathways. Investigates the safety and efficacy of psychedelics in controlled settings.
Director / Lead
James Rucker
Website
www.kcl.ac.ukFocus Areas
10
Studies
About
A leading Czech research institute with a long tradition in psychedelic science. Conducts preclinical and clinical studies on psilocybin and novel psychedelic compounds.
Director / Lead
Tomas Palenicek
Website
www.nudz.czFocus Areas
8
Studies
About
A medical research organization conducting phase 2 clinical trials of psilocybin for major depressive disorder. Focused on developing psilocybin as an FDA-approved medicine.
Director / Lead
Charles Raison
Website
www.usona.orgFocus Areas
8
Studies
About
A translational research program at UCSF studying psilocybin, MDMA, and ketamine across multiple psychiatric conditions. Focuses on bridging neuroscience and clinical applications.
Director / Lead
Joshua Woolley
Website
psychedelics.ucsf.eduFocus Areas
8
Studies
About
A clinical-stage biopharmaceutical company developing psychedelic-inspired therapies. Lead program MM120 (LSD) targets generalized anxiety disorder with promising phase 2b results.
Director / Lead
Robert Barrow
Website
mindmed.coFocus Areas
8
Studies
About
A European non-profit promoting psychedelic research, education, and therapy. Organizes the INSIGHT conference and develops evidence-based training programs for psychedelic therapists.
Director / Lead
Henrik Jungaberle
Website
mind-foundation.orgFocus Areas
8
Studies
About
An international center for ethnobotanical education, research, and service. Specializes in ayahuasca and ibogaine research, advocating for evidence-based policy on traditional plant medicines.
Director / Lead
Benjamin De Loenen
Website
www.iceers.orgFocus Areas
7
Studies
About
MGH's dedicated center exploring the neurobiological mechanisms of psychedelics. Combines brain imaging with clinical trials to understand how psychedelics produce therapeutic effects.
Director / Lead
Jerrold Rosenbaum
Website
www.massgeneral.orgFocus Areas
6
Studies
About
Yale's interdisciplinary research group investigating psilocybin and ketamine for depression, migraine, and substance use disorders. Combines neuroscience with clinical psychiatry.
Director / Lead
Jordan Sloshower
Website
medicine.yale.eduFocus Areas
6
Studies
About
A biopharmaceutical company developing proprietary psychedelic molecules for psychiatric disorders. Advancing deuterated psilocybin (CYB003) and DMT-based treatments through clinical trials.
Director / Lead
Doug Drysdale
Website
www.cybin.comFocus Areas
6
Studies
About
An independent scientific body providing evidence-based information on drugs. Conducts the Psilodep trials studying psilocybin for depression and advocates for evidence-based drug policy.
Director / Lead
David Nutt
Website
www.drugscience.org.ukFocus Areas
6
Studies
About
Conducts clinical trials investigating psilocybin and MDMA for psychiatric disorders. Part of the Netherlands' growing psychedelic research ecosystem with strong neuroimaging capabilities.
Director / Lead
Matthijs Bossong
Website
www.umcutrecht.nlFocus Areas
6
Studies
About
Israel's leading psychedelic research program, studying MDMA for PTSD and psilocybin for depression. Benefits from Israel's progressive regulatory environment for psychedelic clinical trials.
Director / Lead
Bernard Lerer
Website
www.huji.ac.ilFocus Areas
5
Studies
About
A clinical research site specializing in psilocybin-assisted therapy for cancer-related distress and major depression. Operates rigorous clinical trials in a therapeutic setting.
Director / Lead
Manish Agrawal
Website
www.sunstonetherapies.comFocus Areas
5
Studies
About
A Canadian mental health company providing psychedelic-assisted therapy services and conducting clinical research. One of the first to receive a psilocybin dealer's license in Canada.
Director / Lead
Payton Nyquvest
Website
numinus.comFocus Areas
5
Studies
About
Advancing noribogaine (DemeRx-1) as a treatment for opioid use disorder. The leading company in ibogaine-derived medicine development with extensive preclinical and clinical data.
Director / Lead
Deborah Mash
Website
demerx.comFocus Areas
5
Studies
About
Germany's leading university hospital conducting clinical psychedelic research. Investigating psilocybin for treatment-resistant depression with advanced neuroimaging techniques.
Director / Lead
Gerhard Grunder
Website
www.charite.deFocus Areas
5
Studies
About
Conducts clinical research on psilocybin and MDMA for addiction and trauma-related conditions. Known for innovative trial designs combining psychedelic therapy with psychotherapy.
Director / Lead
Celia Morgan
Website
www.exeter.ac.ukFocus Areas
5
Studies
About
A leading Australian academic institution conducting clinical trials of psilocybin and MDMA. Developed Australia's first comprehensive psychedelic therapist training program.
Director / Lead
Paul Liknaitzky
Website
www.monash.eduFocus Areas
5
Studies
About
A life sciences company developing psychedelic and non-psychedelic compounds for inflammation and neuropsychiatry. Exploring low-dose LSD for Alzheimer's disease treatment.
Director / Lead
Shlomi Raz
Website
www.eleusis.comFocus Areas
4
Studies
About
Conducting clinical research on psilocybin pharmacology and its therapeutic applications in depression and addiction. Collaborates closely with the Usona Institute.
Director / Lead
Paul Hutson
Website
www.wisc.eduFocus Areas
4
Studies
About
A clinical-stage biotech developing psychedelic medicines. Lead program BPL-003 (5-MeO-DMT) explores short-duration psychedelic therapy for treatment-resistant depression.
Director / Lead
Cosmo Feilding-Mellen
Website
beckleypsytech.comFocus Areas
4
Studies
About
Investigates the neural and psychological effects of psychedelics with a focus on treatment-resistant depression. Collaborates with other Dutch universities on multi-site clinical trials.
Director / Lead
Nic van der Wee
Website
www.universiteitleiden.nlFocus Areas
4
Studies
About
Australia's leading psychedelic medicine advocacy organization. Instrumental in securing TGA approval for MDMA and psilocybin prescribing by authorized psychiatrists in 2023.
Director / Lead
Peter Hunt
Website
mindmedicineaustralia.org.auFocus Areas
4
Studies
About
A clinical-stage biopharmaceutical company focused on 5-MeO-DMT (mebufotenin) for treatment-resistant depression. Advancing GH001 through clinical development with a unique rapid-onset approach.
Director / Lead
Florian Brand
Website
ghres.comFocus Areas
3
Studies
About
Operates ketamine-assisted therapy clinics across North America and develops novel psychedelic molecules. Pioneered the FT-104 psilocybin prodrug program.
Director / Lead
Ronan Levy
Website
www.fieldtriphealth.comFocus Areas
3
Studies
About
A biotech company developing novel psychedelic compounds for PTSD and addiction. Advancing MYCO-001, a proprietary psilocybin formulation, through clinical development.
Director / Lead
Joshua Bartch
Website
www.mydecine.comFocus Areas
3
Studies
About
Developing psilocybin-assisted therapy for chronic pain conditions including fibromyalgia and binge eating disorder. Advancing TRP-8803 through clinical trials.
Director / Lead
Jim Darnell
Website
www.tryptherapeutics.comFocus Areas
3
Studies
About
One of Germany's first specialized clinics offering ketamine-assisted therapy for treatment-resistant depression. Expanding into psilocybin therapy as regulatory frameworks evolve.
Director / Lead
Dmitrij Achelrod
Website
ovfrankfurt.deFocus Areas
3
Studies
About
Sweden's emerging center for psychedelic research, studying psilocybin for depression and exploring ketamine mechanisms. Part of Scandinavia's growing interest in psychedelic medicine.
Director / Lead
Mikael Landen
Website
www.gu.seFocus Areas
3
Studies
About
A legal psilocybin retreat center in the Netherlands offering structured therapeutic experiences with psilocybin truffles. Combines clinical protocols with supportive therapeutic environments.
Director / Lead
Myles Katz
Website
www.synthesisinstitute.comFocus Areas
3
Studies
About
A Spanish research foundation advancing clinical psychedelic studies in the Iberian Peninsula. Focuses on psilocybin and MDMA-assisted therapies within the European regulatory framework.
Director / Lead
Jose Carlos Bouso
Website
beckleymed.orgFocus Areas
3
Studies
About
A specialty pharmaceutical company developing ketamine and psilocybin-based treatments. Advancing a ketamine microneedle patch for chronic pain and depression.
Director / Lead
Fabio Chianelli
Website
www.pharmather.comFocus Areas
3
Studies
About
A developmental-stage biopharmaceutical company focused on psilocybin and ketamine formulations for neurological and psychiatric conditions including PTSD and fibromyalgia.
Director / Lead
Eric Weisblum
Website
www.silopharma.comFocus Areas
3
Studies
About
New Zealand's leading psychedelic research group studying psilocybin pharmacology and MDMA-assisted therapy. Combines EEG and pharmacokinetic approaches to understand psychedelic mechanisms.
Director / Lead
Suresh Muthukumaraswamy
Website
www.auckland.ac.nzFocus Areas
2
Studies
About
A Canadian non-profit advocating for legal psilocybin therapy access for patients with terminal illness. Successfully secured the first Section 56 exemptions for psilocybin therapy in Canada.
Director / Lead
Spencer Hawkswell
Website
therapsil.caFocus Areas
2
Studies
About
Finland's pioneering academic institution exploring psychedelic-assisted therapy. Developing clinical protocols for psilocybin research within the Nordic healthcare framework.
Director / Lead
Samuli Saarni
Website
www.helsinki.fiFocus Areas
2
Studies
About
A Dutch biotech company developing novel psychedelic formulations with optimized pharmacokinetic profiles. Focused on creating shorter-duration, more controllable psychedelic experiences.
Director / Lead
Rob van den Berg
Website
www.mindshift.nlFocus Areas
2
Studies
About
A biotechnology company focused on developing DMT-based therapies for substance use disorders. Advancing EB-373, a proprietary DMT prodrug, through preclinical development.
Director / Lead
Timothy Ko
Website
www.entheonbiomedical.comFocus Areas